iX Biopharma

PhillipCapital 'remains confident' in iX Biopharma’s growth prospects upon China agreement - THE EDGE SINGAPORE

Broker's Calls

PhillipCapital 'remains confident' in iX Biopharma’s growth prospects upon China agreement

PhillipCapital has kept its "buy" recommendation with the same target price of 44.5 cents.
iX Biopharma enters agreement with Chinese pharmaceutical distributor to tap China market - THE EDGE SINGAPORE

Deals, joint ventures & alliances

iX Biopharma enters agreement with Chinese pharmaceutical distributor to tap China market

iX Biopharma has partnered with China Resources Pharmaceutical Group to distribute products in China.
973 Brokers' Digest - THE EDGE SINGAPORE

Broker's Calls

973 Brokers' Digest

Take a look at these six stocks this week, including DBS, Starhub and ST Engineering.
iX Biopharma remains a 'buy' from PhillipCapital despite $2.8 million net loss in 1H21 - THE EDGE SINGAPORE

Broker's Calls

iX Biopharma remains a 'buy' from PhillipCapital despite $2.8 million net loss in 1H21

PhillipCapital is maintaining its “buy” call on iX Biopharma, but at a lower target price of 44.5 cents.
IX Biopharma appoints Eva Tan as CCO  - THE EDGE SINGAPORE

New appointments

IX Biopharma appoints Eva Tan as CCO

Speciality pharmaceutical company iX Biopharma has appointed Eva Tan as its new chief commercial officer.
PhillipCapital eyes year-end STI at 3,200 - THE EDGE SINGAPORE

Positioning for the recovery

PhillipCapital eyes year-end STI at 3,200

“Investors are positioning ahead of the expected normality to pre-Covid-19 economic conditions," says PhillipCapital.
iX Biopharma obtains approval and registration of male erectile dysfunction drug in Singapore - THE EDGE SINGAPORE

Company in the news

iX Biopharma obtains approval and registration of male erectile dysfunction drug in Singapore

The drug will be supplied via licensed medical practitioners in Singapore.

Broker's Calls

Phillip Securities initiates 'buy' for iX Biopharma on prospect of turning profitable in FY21

The biotech company could finally turn profitable in FY21 as revenue could be bumped up by as much as 250%, says the brokerage.
iX Biopharma secures Australia's GMP licence for its testing laboratory - THE EDGE SINGAPORE

Company in the news

iX Biopharma secures Australia's GMP licence for its testing laboratory

Shares in iX Biopharma closed flat at 24 cents on September 25.
iX Biopharma secures Israel patent for WaferiX - THE EDGE SINGAPORE

Company in the news

iX Biopharma secures Israel patent for WaferiX

iX Biopharma says its intellectual property rights for its sublingual wafer technology is now secured in five continents.
×